Author: Anna Kiyhankhadiv (1)
Lorenz Deutschenbaur, Johannes Beck, Anna Kiyhankhadiv, Markus Mühlhauser, Stefan Borgwardt, Marc Walter, Gregor Hasler, Daniel Sollberger, Undine E Lang
Major depression is a common, recurrent mental illness that affects millions of people worldwide. Recently, a unique fast neuroprotective and antidepressant treatment effect has been observed by ketamine, which acts via the glutamatergic system. Hence, a steady accumulation of evidence supporting a role for the excitatory amino acid neurotransmitter (EAA) glutamate in the treatment of depression has been observed in the last years.
View Full Text PDF Listings View primary source full text article PDFs.